• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于癌症治疗的基于树突状细胞的疫苗的研发。

Generation of dendritic cell-based vaccines for cancer therapy.

作者信息

Reinhard G, Märten A, Kiske S M, Feil F, Bieber T, Schmidt-Wolf I G H

机构信息

Klinik und Poliklinik für Dermatologie der Rheinischen Friedrich-Wilhelms-Universität Bonn, Germany.

出版信息

Br J Cancer. 2002 May 20;86(10):1529-33. doi: 10.1038/sj.bjc.6600316.

DOI:10.1038/sj.bjc.6600316
PMID:12085199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2746586/
Abstract

Dendritic cells play a major role in the generation of immunity against tumour cells. They can be grown under various culture conditions, which influence the phenotypical and functional properties of dendritic cells and thereby the consecutive immune response mainly executed by T cells. Here we discuss various conditions, which are important during generation and administration of dendritic cells to elicit a tumouricidal T cell-based immune response.

摘要

树突状细胞在针对肿瘤细胞的免疫反应产生过程中发挥着主要作用。它们可以在多种培养条件下生长,这些条件会影响树突状细胞的表型和功能特性,进而影响主要由T细胞执行的后续免疫反应。在此,我们讨论在树突状细胞的生成和给药过程中各种重要条件,以引发基于T细胞杀瘤作用的免疫反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/845c/2746586/7cfcd7761def/86-6600316f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/845c/2746586/7cfcd7761def/86-6600316f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/845c/2746586/7cfcd7761def/86-6600316f1.jpg

相似文献

1
Generation of dendritic cell-based vaccines for cancer therapy.用于癌症治疗的基于树突状细胞的疫苗的研发。
Br J Cancer. 2002 May 20;86(10):1529-33. doi: 10.1038/sj.bjc.6600316.
2
Dendritic cell vaccines for leukemia patients.用于白血病患者的树突状细胞疫苗。
Expert Rev Anticancer Ther. 2007 Mar;7(3):275-83. doi: 10.1586/14737140.7.3.275.
3
Genetically modified tumour vaccines--where we are today.转基因肿瘤疫苗——我们目前的进展
Cancer Treat Rev. 1999 Feb;25(1):29-46. doi: 10.1053/ctrv.1998.0104.
4
DC preparations for therapy.用于治疗的树突状细胞制剂。
Cytotherapy. 2004;6(2):99-104. doi: 10.1080/14653240410005285.
5
The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.细胞因子基因共转导对使用表达肿瘤相关抗原的基因修饰树突状细胞进行癌症疫苗治疗的增强作用。
Int J Oncol. 2006 Apr;28(4):947-53.
6
DC-based cancer vaccines: lessons from clinical trials.基于树突状细胞的癌症疫苗:临床试验的经验教训。
Cytotherapy. 2004;6(2):122-7. doi: 10.1080/14653240410005267.
7
Apoptosis of monocytes and the influence on yield of monocyte-derived dendritic cells.单核细胞凋亡及其对单核细胞衍生树突状细胞产量的影响。
J Immunol Methods. 2004 Nov;294(1-2):67-80. doi: 10.1016/j.jim.2004.08.010.
8
Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.使用Flt3配体和CD40配体生成的血液树突状细胞能有效地激活癌症患者的CD8+T细胞。
J Immunother. 2006 Sep-Oct;29(5):499-511. doi: 10.1097/01.cji.0000211299.29632.8c.
9
[Immunology in medical practice. XXV. Use of dendritic cells in the immunotherapy of cancer].[医学实践中的免疫学。第二十五部分。树突状细胞在癌症免疫治疗中的应用]
Ned Tijdschr Geneeskd. 1999 Nov 27;143(48):2408-14.
10
[The Langerhans cell: from in vitro production to use in cellular immunotherapy].[朗格汉斯细胞:从体外培养到用于细胞免疫治疗]
J Soc Biol. 2001;195(1):69-74.

引用本文的文献

1
Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives.胶质母细胞瘤治疗的免疫治疗策略:当前挑战与未来展望
Cancers (Basel). 2024 Mar 25;16(7):1276. doi: 10.3390/cancers16071276.
2
Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies.基于抗体的免疫治疗策略治疗血液系统恶性肿瘤。
Biomed Res Int. 2020 Sep 17;2020:4956946. doi: 10.1155/2020/4956946. eCollection 2020.
3
Immunotherapies for non-small-cell lung cancer and mesothelioma.非小细胞肺癌和间皮瘤的免疫疗法。

本文引用的文献

1
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.独特型脉冲树突状细胞疫苗治疗B细胞淋巴瘤:35例患者的临床及免疫反应
Blood. 2002 Mar 1;99(5):1517-26. doi: 10.1182/blood.v99.5.1517.
2
Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy.基于树突状细胞的异种抗原疫苗接种用于前列腺癌免疫治疗
J Immunol. 2001 Dec 15;167(12):7150-6. doi: 10.4049/jimmunol.167.12.7150.
3
Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.
Lancet Oncol. 2012 Jul;13(7):e301-10. doi: 10.1016/S1470-2045(12)70126-2. Epub 2012 Jun 28.
4
Enhanced immunity against hepatoma induced by dendritic cells pulsed with Hsp70-H22 peptide complexes and CD40L.树突状细胞负载 HSP70-H22 肽复合物和 CD40L 增强抗肝癌免疫
J Cancer Res Clin Oncol. 2012 Jun;138(6):917-26. doi: 10.1007/s00432-012-1166-6. Epub 2012 Feb 11.
5
Stimulatory effect of Echinacea purpurea extract on the trafficking activity of mouse dendritic cells: revealed by genomic and proteomic analyses.松果菊提取物对小鼠树突状细胞运输活性的刺激作用:通过基因组和蛋白质组分析揭示。
BMC Genomics. 2010 Nov 1;11:612. doi: 10.1186/1471-2164-11-612.
6
Genomics and proteomics of immune modulatory effects of a butanol fraction of echinacea purpurea in human dendritic cells.紫锥菊丁醇组分对人树突状细胞免疫调节作用的基因组学和蛋白质组学研究
BMC Genomics. 2008 Oct 13;9:479. doi: 10.1186/1471-2164-9-479.
7
Heat-shocked tumor cell lysate-pulsed dendritic cells induce effective anti-tumor immune response in vivo.热休克肿瘤细胞裂解物脉冲处理的树突状细胞在体内诱导有效的抗肿瘤免疫反应。
World J Gastroenterol. 2006 Jan 21;12(3):473-8. doi: 10.3748/wjg.v12.i3.473.
8
A peptide-loaded dendritic cell based cytotoxic T-lymphocyte (CTL) vaccination strategy using peptides that span SIV Tat, Rev, and Env overlapping reading frames.一种基于负载肽的树突状细胞的细胞毒性T淋巴细胞(CTL)疫苗接种策略,该策略使用跨越SIV Tat、Rev和Env重叠阅读框的肽。
Retrovirology. 2006 Jan 6;3:1. doi: 10.1186/1742-4690-3-1.
9
Release of iC3b from apoptotic tumor cells induces tolerance by binding to immature dendritic cells in vitro and in vivo.凋亡肿瘤细胞释放的iC3b通过在体外和体内与未成熟树突状细胞结合诱导免疫耐受。
Cancer Immunol Immunother. 2006 Jan;55(1):31-8. doi: 10.1007/s00262-005-0690-5. Epub 2005 Oct 27.
10
Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons.来自1型人类免疫缺陷病毒感染者的树突状细胞对外源性HLA I类肽的加工与呈递
J Virol. 2005 Mar;79(5):3052-62. doi: 10.1128/JVI.79.5.3052-3062.2005.
用肿瘤裂解物脉冲处理的树突状细胞对小儿实体瘤患者进行疫苗接种可扩增特异性T细胞并介导肿瘤消退。
Cancer Res. 2001 Dec 1;61(23):8513-9.
4
Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination.通过树突状细胞疫苗接种对甲状腺髓样癌进行免疫治疗。
J Clin Endocrinol Metab. 2001 Oct;86(10):4965-9. doi: 10.1210/jcem.86.10.7949.
5
Transfection of dendritic cells (DCs) with the CIITA gene: increase in immunostimulatory activity of DCs.用CIITA基因转染树突状细胞(DCs):DCs免疫刺激活性增强。
Cancer Gene Ther. 2001 Mar;8(3):211-9. doi: 10.1038/sj.cgt.7700292.
6
Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells.一名患者在接种人肽脉冲树突状细胞疫苗后发生过敏反应,其体内存在针对牛血清白蛋白的IgE抗体。
Cancer Immunol Immunother. 2000 Jun;49(3):152-6. doi: 10.1007/s002620050614.
7
Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease.针对与正常宿主细胞共有的肿瘤抗原进行树突状细胞免疫疗法会导致严重的自身免疫性疾病。
J Exp Med. 2000 Mar 6;191(5):795-804. doi: 10.1084/jem.191.5.795.
8
Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy.未成熟的人单核细胞衍生树突状细胞在皮内注射用于黑色素瘤免疫治疗后迅速迁移至引流淋巴结。
Melanoma Res. 1999 Oct;9(5):474-81. doi: 10.1097/00008390-199910000-00007.
9
Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.用mage-3A1肽脉冲处理的成熟单核细胞衍生树突状细胞进行疫苗接种,可扩增特异性细胞毒性T细胞,并诱导晚期IV期黑色素瘤的一些转移灶消退。
J Exp Med. 1999 Dec 6;190(11):1669-78. doi: 10.1084/jem.190.11.1669.
10
Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application.从白细胞分离产物中生成大量完全成熟且稳定的树突状细胞用于临床应用。
J Immunol Methods. 1999 Feb 1;223(1):1-15. doi: 10.1016/s0022-1759(98)00208-7.